Recon: Pfizer withdraws sickle cell drug Oxbryta from worldwide markets; Evotec, Novo Nordisk partner on stem cell therapy manufacturing

• Head of national stockpile addresses Congress’ criticisms of outbreak response (STAT)
• AbbVie Parkinson’s drug helps improve symptoms in late-stage study (STAT)
• Why Biohaven will test the FDA’s regulatory limits (STAT)
• US Senate votes to hold Steward Health CEO in criminal contempt (Reuters)
• Merck's colorectal cancer therapy fails late-stage trial (Reuters)
• Exclusive: J&J folds cardiovascular and metabolic drug unit (Endpoints)
• FDA adcomm votes to limit Opdivo, Keytruda use in stomach cancer based on key biomarker (Endpoints)
• CSL Seqirus inks fifth contract with BARDA, making the partnership now worth $1.14B (Endpoints)

• The little-known Chinese biotech whose cancer drug beat Keytruda has global ambitions (STAT)
• Pfizer pulls sickle cell treatment Oxbryta off global markets (STAT) (Reuters)
• EU regulator recommends suspension of Pfizer's sickle cell disease treatment (Reuters)
• EMA Discusses Fatal Events That Prompted Pfizer To Pull Oxbryta From Global Markets (Pink Sheet)
• Pfizer v Moderna COVID vaccine patents battle to go to appeal in UK (Reuters)
• Slow progress on Pfizer's plan to sell drugs to low-income nations at not-for-profit price, says CEO (Reuters)
• Bavarian Nordic signs agreement with UNICEF for one million mpox vaccines (Reuters)

• Evotec and Novo Nordisk in technology development partnership (Reuters)
• Amid push to redefine itself, Sanofi names new chief scientific officer (STAT)
• ARCH Venture Partners raises $3 billion for a new biotech fund (STAT)
• AstraZeneca in AI collaboration with Immunai to inform cancer drug trials (Reuters)
• Healthcare firm Guardian Pharmacy raises $112 mln in US IPO (Reuters)
• Masimo founder Joe Kiani resigns as CEO following ouster from board (Reuters)
• Obesity drug developer BioAge Labs aims up to $640 mln valuation in upsized US IPO (Reuters)
• KKR, GIC hire banks to sell stakes in $3.2 bln Metro Pacific Health, sources say (Reuters)
• Biogen walks away from Sage's essential tremor drug after mid-stage flop, pill's future in question (Endpoints)
• AGC Biologics to lay off 95 workers; Vertex taps Lonza to manufacture Casgevy (Endpoints)
• SIGA is 'deeply angered' by former exec's 'inaccurate' comments about mpox antiviral (Endpoints)
• Repair, Genevant ink deal worth up to $107M; 858 Therapeutics raises $50M (Endpoints)
• Instacart partners with 9amHealth to combine weight loss drugs with healthy foods (Endpoints)

• Can MRIs ensure prostate cancer screening does more good than harm? (STAT)
• Sleep apnea alert on Apple Watch: What does it mean, and how does it work? (STAT)
• Congress again delays steep cuts in Medicare lab payments (MedTech Dive)
• FDA proposes reclassifying hepatitis B assays (MedTech Dive)

• Two reports, two dramatically different views of nonprofit hospitals’ tax breaks (STAT)
• Biotech’s real estate market is still upside down (STAT)
• Generic drug lobby taps former BIO exec as new CEO (STAT)
• Washington state's abortion pill stockpile is insurance against Trump win, governor says (Reuters)
• A New Book on Hatch-Waxman – Breaking the Medicine Monopolies: Reflections of a Generic Drug Pioneer (FDA Law Blog)